Literature DB >> 32754942

Simultaneous proton density fat-fraction and R 2 imaging with water-specific T1 mapping (PROFIT1 ): application in liver.

Richard B Thompson1, Kelvin Chow2, Diana Mager3, Joseph J Pagano1, Justin Grenier1.   

Abstract

PURPOSE: To describe and validate a simultaneous proton density fat-fraction (PDFF) imaging and water-specific T1 mapping (T1(Water) ) approach for the liver (PROFIT1 ) with R 2 ∗ mapping and low sensitivity to B 1 + calibration or inhomogeneity.
METHODS: A multiecho gradient-echo sequence, with and without saturation preparation, was designed for simultaneous imaging of liver PDFF, R 2 ∗ , and T1(Water) (three slices in ~13 seconds). Chemical-shift-encoded MRI processing yielded fat-water separated images and R 2 ∗ maps. T1(Water)  calculation utilized saturation and nonsaturation-recovery water-separated images. Several variable flip angle schemes across k-space (increasing flip angles in sequential RF pulses) were evaluated for minimization of T1 weighting, to reduce the B 1 + dependence of T1(Water)  and PDFF (reduced flip angle dependence). T1(Water)  accuracy was validated in mixed fat-water phantoms, with various PDFF and T1 values (3T). In vivo application was illustrated in five volunteers and five patients with nonalcoholic fatty liver disease (PDFF, T1(Water) , R 2 ∗ ).
RESULTS: A sin3 (θ) flip angle pattern (0 < θ < π/2 over k-space) yielded the largest PROFIT1 signal yield with negligible B 1 + dependence for both T1(Water) and PDFF. Mixed fat-water phantom experiments illustrated excellent agreement between PROFIT1 and gold-standard spectroscopic evaluation of PDFF and T1(Water)  (<1% T1 error). In vivo PDFF, T1(Water) , and R 2 ∗ maps illustrated independence of the PROFIT1 values from B 1 + inhomogeneity and significant differences between volunteers and patients with nonalcoholic fatty liver disease for T1(Water) (927 ± 56 ms vs. 1033 ± 23 ms; P < .05) and PDFF (2.0% ± 0.8% vs. 13.4% ± 5.0%, P < .05).  R 2 ∗ was similar between groups.
CONCLUSION: The PROFIT1 pulse sequence provides fast simultaneous quantification of PDFF, T1(Water) , and R 2 ∗ with minimal sensitivity to B 1 + miscalibration or inhomogeneity.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  PDFF; T1 mapping; fat; fibrosis; liver; magnetic resonance imaging

Mesh:

Substances:

Year:  2020        PMID: 32754942     DOI: 10.1002/mrm.28434

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  3 in total

1.  Free-breathing multitasking multi-echo MRI for whole-liver water-specific T1 , proton density fat fraction, and R 2 quantification.

Authors:  Nan Wang; Tianle Cao; Fei Han; Yibin Xie; Xiaodong Zhong; Sen Ma; Alan Kwan; Zhaoyang Fan; Hui Han; Xiaoming Bi; Mazen Noureddin; Vibhas Deshpande; Anthony G Christodoulou; Debiao Li
Journal:  Magn Reson Med       Date:  2021-08-21       Impact factor: 4.668

2.  Decongestive progressive resistance exercise with an adjustable compression wrap for breast cancer-related lymphoedema (DREAM): protocol for a randomised controlled trial.

Authors:  Mona M Al Onazi; Kristin L Campbell; Richard B Thompson; Sunita Ghosh; John R Mackey; Anne Muir; Margaret L McNeely
Journal:  BMJ Open       Date:  2022-04-04       Impact factor: 2.692

3.  Remission of type 2 diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction among young adults: the RESET for REMISSION randomised controlled trial protocol.

Authors:  Kaberi Dasgupta; Thomas Yates; Normand Boulé; Joseph Henson; Stéphanie Chevalier; Emma Redman; Deborah Chan; Matthew McCarthy; Julia Champagne; Frank Arsenyadis; Jordan Rees; Deborah Da Costa; Edward Gregg; Roseanne Yeung; Michelle Hadjiconstantinou; Abhishek Dattani; Matthias G Friedrich; Kamlesh Khunti; Elham Rahme; Isabel Fortier; Carla M Prado; Mark Sherman; Richard B Thompson; Melanie J Davies; Gerry P McCann
Journal:  BMJ Open       Date:  2022-09-21       Impact factor: 3.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.